Should You Continue to Hold Medtronic Stock in Your Portfolio Now?
Investors stay optimistic about MDT due to its strength in the Cardiovascular portfolio.
Medtronic (MDT) Stock Declines While Market Improves: Some Information for Investors
Medtronic (MDT) closed the most recent trading day at $84.25, moving -1.01% from the previous trading session.
Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the closing of the recent trading day, Medtronic (MDT) stood at $83.62, denoting a +0.55% change from the preceding trading day.
Is Medtronic Stock a Buy Pre-Q4 Earnings? Key Metrics to Watch
Despite challenges, Medtronic demonstrates the resilience of its underlying business fundamentals, delivering consistent mid-single-digit organic revenue growth.
Medtronic to announce financial results for its fourth quarter and full fiscal year 2025
GALWAY, Ireland , May 7, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2025 on Wednesday, May 21, 2025. A news release will be issued at approximately 5:45 a.m.
New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women
Star Jones, award winning television personality & women's heart health advocate, helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign GALWAY, Ireland , May 7, 2025 /PRNewswire/ -- A new Medtronic-sponsored survey of women ages 30-50 reveals a significant gap in awareness and discussion around heart health among women and their mother-figures. Despite cardiovascular disease being the #1 killer of women in the U.S., many women are still unaware of the risk and the importance of heart health.
This Magnificent High-Yield Dividend Stock Just Became an Even Better Buy
Medical device specialist Medtronic (MDT 1.38%) has not performed well over the past five years; the stock has significantly lagged broader equities. One of the issues it's encountered is slow revenue growth.
Medtronic (MDT) Surpasses Market Returns: Some Facts Worth Knowing
Medtronic (MDT) closed the most recent trading day at $84.85, moving +1.54% from the previous trading session.
Medtronic (MDT) Rises Higher Than Market: Key Facts
Medtronic (MDT) concluded the recent trading session at $84.76, signifying a +0.19% move from its prior day's close.
Smart Pills Market Industry Trend Analysis, and Forecast 2025-2034, with Profiles of ANX Robotica, Bodycap, CapsoVision, Check-Cap, etectRx, Intromedic, Medtronic, Otsuka, Olympus and RF
Key growth drivers include the rise of gastrointestinal disorders and demand for non-invasive diagnostics. Smart pills, equipped with sensors and AI, facilitate real-time monitoring and personalized medicine. North America leads with USD 455.5 million in 2024. The market benefits from tech advancements, an aging population, and robust healthcare infrastructure, paving the way for continuous growth. Key growth drivers include the rise of gastrointestinal disorders and demand for non-invasive diagnostics. Smart pills, equipped with sensors and AI, facilitate real-time monitoring and personalized medicine. North America leads with USD 455.5 million in 2024. The market benefits from tech advancements, an aging population, and robust healthcare infrastructure, paving the way for continuous growth.
Medtronic Afferaâ„¢ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients
One-year clinical trial data for the next-generation, investigational, Sphere-360â„¢ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib Dual-energy (RF/PF), focal Sphere-9â„¢ catheter demonstrates efficacy for linear ablation in persistent AFib Medtronic continues legacy of leadership in innovation, showcasing arrhythmia management portfolio at Heart Rhythm Society annual meeting GALWAY, Ireland and SAN DIEGO , April 26, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Afferaâ„¢ family of technologies, including the next-generation Sphere-360â„¢ single-shot pulsed field ablation (PFA) catheter and the groundbreaking Sphere-9â„¢ combination mapping and dual-energy focal PFA catheter. Data were presented in High Impact Science Sessions at the Heart Rhythm Society 2025 Annual Meeting in San Diego; the Sphere-360 study was simultaneously published in the Heart Rhythm Journal.
2 Outstanding Dividend Stocks to Buy and Hold For 20 Years
Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold on through market volatility. In fact, it's still a great time to invest in companies that have excellent underlying businesses and attractive long-term prospects.
